Boston Scientific (NYSE:BSX)‘s stock had its “market perform” rating reaffirmed by equities researchers at Stephens in a research note issued to investors on Monday, The Fly reports. They presently have a $40.00 price target on the medical equipment provider’s stock. Stephens’ price target would indicate a potential upside of 12.61% from the company’s previous close.

Several other analysts also recently weighed in on the stock. Jefferies Financial Group upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and lifted their price objective for the company from $34.00 to $42.00 in a research report on Tuesday, September 4th. Morgan Stanley lifted their price objective on shares of Boston Scientific from $38.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. Barclays initiated coverage on shares of Boston Scientific in a research report on Monday, October 15th. They issued an “overweight” rating and a $43.00 price objective on the stock. Wells Fargo & Co lifted their price objective on shares of Boston Scientific from $38.00 to $42.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. Finally, Needham & Company LLC reiterated a “strong-buy” rating and issued a $43.00 price objective (up from $39.00) on shares of Boston Scientific in a research report on Friday, September 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $39.12.

Shares of Boston Scientific stock traded down $1.69 during trading hours on Monday, reaching $35.52. The company’s stock had a trading volume of 754,162 shares, compared to its average volume of 7,667,250. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 0.78. Boston Scientific has a one year low of $24.54 and a one year high of $39.44. The company has a market cap of $51.49 billion, a P/E ratio of 28.26, a PEG ratio of 2.44 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.01. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $0.31 EPS. As a group, sell-side analysts predict that Boston Scientific will post 1.39 earnings per share for the current year.

In other news, SVP Wendy Carruthers sold 1,500 shares of Boston Scientific stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $36.64, for a total value of $54,960.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $38.80, for a total transaction of $194,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 417,928 shares of company stock worth $15,499,426. 0.73% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in BSX. Sei Investments Co. lifted its stake in Boston Scientific by 7.8% in the second quarter. Sei Investments Co. now owns 3,853,853 shares of the medical equipment provider’s stock valued at $126,021,000 after acquiring an additional 278,777 shares during the last quarter. Waddell & Reed Financial Inc. acquired a new stake in Boston Scientific in the second quarter valued at approximately $5,559,000. Cubist Systematic Strategies LLC lifted its stake in Boston Scientific by 3.1% in the second quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after acquiring an additional 1,547 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Boston Scientific by 2.0% in the second quarter. Public Employees Retirement System of Ohio now owns 965,855 shares of the medical equipment provider’s stock valued at $31,583,000 after acquiring an additional 19,383 shares during the last quarter. Finally, First Republic Investment Management Inc. lifted its stake in Boston Scientific by 6.0% in the second quarter. First Republic Investment Management Inc. now owns 102,653 shares of the medical equipment provider’s stock valued at $3,357,000 after acquiring an additional 5,812 shares during the last quarter. 92.27% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: 52-Week High/Low

The Fly

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.